Mesoblast Limited (MESO) Discusses Cellular Medicine Platforms and Innovations at R&D Day April 8, 2026 8:00 AM EDT
Company Participants
Paul Hughes – Global Head of Corporate Communications & Joint Company Secretary
Silviu Itescu – Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director
Marcelo Santoro – Chief Commercial Officer
Michael Schuster – Co-Founder and Head of Pharma Partnering
Roger Brown
Kenneth Borow – Executive
Eric Rose – Chief Medical Officer & Executive Director
Daniel Devine
Justin Horst – Head of Manufacturing
James O’Brien – Chief Financial Officer
Michael Schuster
Conference Call Participants
Joanne Kurtzberg
Susan Prockop
Douglas Beall
Emerson Perin
Saad J. Kenderian
Thaddeus Barney – Piper Sandler & Co., Research Division
Thomas Shrader – BTIG, LLC, Research Division
Douglas P. Beall
Michael Okunewitch – Maxim Group LLC, Research Division
Edward Tenthoff – Piper Sandler & Co., Research Division
Conversation
Paul Hughes
Global Head of Corporate Communications & Joint Company Secretary
Good morning, and welcome, everyone, to Mesoblast’s inaugural R&D Day. We’ve got a wonderful morning planned and appreciate you all investing the time to come along and hear the Mesoblast story.
Before we get started, I’ll just draw your attention to the slide, the forward-looking statement that I’ve got displayed on the screen. Okay. So the format will be presentations from Mesoblast program heads and our leaders. And they will be followed by a fireside chat with KOLs, and then we’ll conclude with Q&A. We’re delighted to have such a distinguished lineup of industry key opinion leaders for you to hear from today, and we’re very grateful for their time.
And with that, I’ll now hand over to Silviu, Mesoblast’s Chief Executive.
Silviu Itescu
Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director
Good morning, everybody, and thank you for coming. We’re very excited to have our inaugural R&D Day and it’s great to have so many friends in the audience. So nice to see
Read the full article here
